Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, Ranganathan P, Jain N, Hanel W, Tsichlis P, Alinari L, Peterson BR, Tao J, Muthusamy N, Baiocchi R, Epperla N, Young KH, Morin R, Sehgal L. Sircar A, et al. Among authors: alinari l. Leukemia. 2023 Oct;37(10):2094-2106. doi: 10.1038/s41375-023-02006-8. Epub 2023 Aug 19. Leukemia. 2023. PMID: 37598282 Free PMC article.
A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas.
Jang JY, Hwang I, Pan H, Yao J, Alinari L, Imada E, Zanettini C, Kluk MJ, Wang Y, Lee Y, Lin HV, Huang X, Di Liberto M, Chen Z, Ballman KV, Cantley LC, Marchionni L, Inghirami G, Elemento O, Baiocchi RA, Chen-Kiang S, Belvedere S, Zheng H, Paik J. Jang JY, et al. Among authors: alinari l. J Clin Invest. 2022 Dec 15;132(24):e160767. doi: 10.1172/JCI160767. J Clin Invest. 2022. PMID: 36282572 Free PMC article.
Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy.
Annunzio K, Cackovic M, Bond D, Sawalha Y, Voorhees TJ, Hanel W, Alinari L, Baiocchi R, Reneau J, Brammer J, Maddocks K, Christian B, Epperla N. Annunzio K, et al. Among authors: alinari l. Blood Adv. 2023 May 23;7(10):2241-2244. doi: 10.1182/bloodadvances.2022008621. Blood Adv. 2023. PMID: 36287222 Free PMC article. No abstract available.
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R. Sher S, et al. Among authors: alinari l. Leukemia. 2023 Feb;37(2):326-338. doi: 10.1038/s41375-022-01758-z. Epub 2022 Nov 14. Leukemia. 2023. PMID: 36376377 Free PMC article.
Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents.
Faisal MS, Hanel W, Voorhees T, Li R, Huang Y, Khan A, Bond D, Sawalha Y, Reneau J, Alinari L, Baiocchi R, Christian B, Maddocks K, Efebera Y, Penza S, Saad A, Brammer J, DeLima M, Jaglowski S, Epperla N. Faisal MS, et al. Among authors: alinari l. Cancer Med. 2023 Apr;12(7):8228-8237. doi: 10.1002/cam4.5631. Epub 2023 Jan 18. Cancer Med. 2023. PMID: 36653918 Free PMC article.
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL, Brown F, Long M, Weigel C, Koirala S, Chung JH, Pray B, Villagomez L, Hinterschied C, Sircar A, Helmig-Mason J, Prouty A, Brooks E, Youssef Y, Hanel W, Parekh S, Chan WK, Chen Z, Lapalombella R, Sehgal L, Vaddi K, Scherle P, Chen-Kiang S, Di Liberto M, Elemento O, Meydan C, Foox J, Butler D, Mason CE, Baiocchi RA, Alinari L. Sloan SL, et al. Among authors: alinari l. Blood. 2023 Sep 7;142(10):887-902. doi: 10.1182/blood.2022019419. Blood. 2023. PMID: 37267517
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.
Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason J, Long M, Chan WK, Prouty A, Chung JH, Zhang Y, Singh S, Youssef Y, Bhagwat N, Chen Z, Chen-Kiang S, Di Liberto M, Elemento O, Sehgal L, Alinari L, Vaddi K, Scherle P, Lapalombella R, Paik J, Baiocchi RA. Brown-Burke F, et al. Among authors: alinari l. Blood Adv. 2023 Oct 24;7(20):6211-6224. doi: 10.1182/bloodadvances.2023009906. Blood Adv. 2023. PMID: 37327122 Free PMC article.
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.
Chan WK, Williams J, Sorathia K, Pray B, Abusaleh K, Bian Z, Sharma A, Hout I, Nishat S, Hanel W, Sloan SL, Yasin A, Denlinger N, Zhang X, Muthusamy N, Vasu S, de Lima M, Yang Y, Baiocchi R, Alinari L. Chan WK, et al. Among authors: alinari l. Exp Hematol Oncol. 2023 Sep 22;12(1):79. doi: 10.1186/s40164-023-00437-8. Exp Hematol Oncol. 2023. PMID: 37740214 Free PMC article.
Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME, Koirala S, Sloan S, Brown-Burke F, Weigel C, Villagomez L, Corps K, Sharma A, Hout I, Harper M, Helmig-Mason J, Tallada S, Chen Z, Scherle P, Vaddi K, Chen-Kiang S, Di Liberto M, Meydan C, Foox J, Butler D, Mason C, Alinari L, Blaser BW, Baiocchi R. Long ME, et al. Among authors: alinari l. Blood Adv. 2024 Jan 9;8(1):150-163. doi: 10.1182/bloodadvances.2023010554. Blood Adv. 2024. PMID: 37782774 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 38193716
109 results